Citadel Advisors’s Palisade Bio PALI Stock Holding History

Citadel Advisors’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Hold	–	-$3K	–	7610
2016 Q2	–	Hold	–	–	–	6757
2016 Q1	–	Hold	–	–	–	6612
2015 Q4	–	Hold	–	–	–	8620
2015 Q3	–	Hold	–	–	–	8125
2015 Q2	–	Hold	–	–	–	7831
2015 Q1	–	Hold	–	–	–	7447
2014 Q4	–	Hold	–	–	–	6631
2014 Q3	–	Hold	–	–	–	6607
2014 Q2	–	Hold	–	–	–	7313
2014 Q1	–	Hold	–	–	–	7312

Other funds holding PALI

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Citadel Advisors's PALI Position: Q2 2026 in Review

Citadel Advisors increased its Palisade Bio (PALI) stake by 7,025% in Q2 2026, buying an estimated $1.97M and bringing the position to 1,016,850 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #6416.

Citadel Advisors first reported a position in PALI in Q4 2018 and has held it in 11 quarters since. The position peaked at $4M in Q4 2025. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

Citadel Advisors held 1,016,850 shares of Palisade Bio worth $2.13M as of Q2 2026.
Citadel Advisors bought 1,002,578 Palisade Bio shares in Q2 2026, an estimated $1.97M.
Palisade Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6416 holding.
Citadel Advisors first reported a position in Palisade Bio in Q4 2018 and has held it in 11 quarters since.
Citadel Advisors's Palisade Bio position peaked at $4M in Q4 2025.
124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.